<DOC>
	<DOC>NCT00151242</DOC>
	<brief_summary>This trial is a study on all-trans retinoic acid in combination with induction and consolidation therapy as well as pegfilgrastim after consolidation therapy in younger patients with newly diagnosed acute myeloid leukemia (AML).</brief_summary>
	<brief_title>Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>First Induction Therapy: - Cytarabine 100 mg/m² cont. i.v. days 1-7 - Idarubicin 12 mg/m² i.v. days 1,3,5 - Etoposide 100 mg/m² i.v. days 1-3 - ± ATRA 45 mg/m² p.o. days 6-8 - ATRA 15 mg/m² p.o. days 9-21 Second Induction Therapy: - Cytarabine 100 mg/m² cont. i.v. days 1-7 - Idarubicin 12 mg/m² i.v. days 1 and 3 - Etoposide 100 mg/m² i.v. days 1-3 - ± ATRA 45 mg/m² p.o. days 6-8 - ATRA 15 mg/m² p.o. days 9-21 Consolidation Therapy: cohort 1 (&lt;= ID 336) - Cytarabine 3 g/m² 2x/die i.v. Tag 1,3,5 - ± ATRA 15 mg/m² p.o. Tag 6-21 - Pegfilgrastim 6 mg s.c day 10 cohort 2 (&gt; ID 336) - Cytarabine 3 g/m² 2x/die i.v. Tag 1,2,3 - ± ATRA 15 mg/m² p.o. Tag 4-21 - Pegfilgrastim 6 mg s.c day 8</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Newly diagnosed AML defined according to the World Health Organization (WHO)classification (excluding acute promyelocytic leukemia [APL]) Ages 1860 years Written informed consent of each patient at study entry. Molecular and cytogenetical diagnostics on initial bone marrow and peripheral blood specimen at the central reference laboratories Bleeding independent of the AML Acute promyelocytic leukemia Uncontrollable infection Participation in a concurrent clinical study Insufficiency of the kidneys (creatinine &gt; 1.5x upper normal serum level), of the liver (bilirubin, AST or AP &gt; 2x upper normal serum level), severe obstructive or restrictive ventilation disorder, heart failure New York Heart Association (NYHA) III/IV Severe neurological or psychiatric disorder interfering with ability to give an informed consent. No consent for registration, storage and processing of the individual diseasecharacteristics and course. Performance status WHO &gt; 2 Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>